Trial Profile

Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide/Abaloparatide (START) Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abaloparatide (Primary) ; Denosumab (Primary) ; Romosozumab (Primary) ; Teriparatide (Primary) ; Zoledronic acid (Primary)
Indications Postmenopausal osteoporosis
Focus Therapeutic Use
Acronyms START

27 Apr 2025 Abaloparatide is also added to the study drugs.
27 Apr 2025 Planned End Date changed from 1 Dec 2025 to 1 May 2027.
27 Apr 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com